DEFR14A: Nuvation Bio Clarifies Voting Procedures for Upcoming Annual Meeting

Nuvation Bio issues a supplement to its proxy statement to clarify voting approval standards for the proposals at the Annual Meeting of Stockholders on September 3, 2024.

Summary

• Nuvation Bio has released a supplement to its proxy statement for the Annual Meeting of Stockholders, scheduled for September 3, 2024.
• The supplement aims to clarify the voting approval standards for the proposals to be presented at the meeting.
• The document revises sections of the original proxy statement related to the election of directors, voting eligibility, quorum requirements, and the number of votes needed to approve each proposal.
• Holders of Class A and Class B stock as of July 29, 2024, are entitled to vote.
• There are 248,245,129 shares of Class A Stock and 1,000,000 shares of Class B Stock outstanding.
• A quorum requires a majority of the voting power of outstanding Class A and Class B shares, and a majority of Class B shares for the election of the Class B director.
• The company will conduct a separate tabulation for Proposal 4 (conversion of Series A Preferred Stock) to comply with NYSE rules, excluding 27,646,255 shares of Class A Stock issued in the Merger from the total shares voted in favor.
• Abstentions and broker non-votes will not affect the outcome of the vote on Proposals 2, 3, 4, and 5.
• Broker non-votes will have no effect on the outcome of the vote on Proposal 1, Proposal 3, or Proposal 4.

Sentiment

Score: 7

Explanation: The document is a procedural update, clarifying voting matters. It is neutral in tone and aims to ensure a smooth and compliant annual meeting. The sentiment is moderately positive as it promotes transparency and shareholder engagement.

Positives

• The supplement provides clarity on the voting process, potentially increasing shareholder participation.
• The company is taking steps to ensure compliance with NYSE rules regarding the separate tabulation of votes for Proposal 4.

Future Outlook

Unless the Board decides to modify its policy regarding the frequency of soliciting advisory votes on the compensation of the Company's named executive officers, the next scheduled say-on-pay vote will be at the 2025 Annual Meeting of Stockholders, in accordance with the current policy to conduct such votes annually.

Industry Context

This announcement is a standard corporate governance procedure related to an upcoming annual meeting. It ensures shareholders are informed about voting rights and procedures, which is crucial for maintaining transparency and accountability.

Stakeholder Impact

• Shareholders are directly impacted by the clarifications regarding voting procedures.
• The supplement ensures that all shareholders understand their voting rights and how their votes will be counted.

Next Steps

• Shareholders should review the supplement and the original proxy statement before voting.
• Shareholders should submit their votes before the Annual Meeting on September 3, 2024.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Voting Rights, Class A Stock, Class B Stock, Nuvation Bio, NYSE, Quorum, Merger, Proposal 4